Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19
Eurasian Journal of Critical Care · 2022
DOI: 10.55994/ejcc.1112050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Critical Care, 2022. Verfasst von Ali SARIDAŞ. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Herhangi bir kurum tarafından destek almamıştır..
Abstract (Originalsprache)
The novel coronavirus disease 2019 (COVID-19) emerged in China in late December 2019 and quickly spread to many countries around the world. Antiviral drugs are candidate treatments for the treatment of COVID-19. Molnupiravir, the first oral antiviral drug, is a drug with anti-RNA polymerase activity and is currently being used for the treatment of COVID-19 patients. In this review, we aimed to discuss the mechanism of action, safety, efficacy and clinical studies of molnupiravir in the treatment of patients with COVID-19.
Förderung
- Herhangi bir kurum tarafından destek almamıştır.
Zitieren
APA
SARIDAŞ, A. (2022). Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19. Eurasian Journal of Critical Care. https://doi.org/10.55994/ejcc.1112050
Vancouver
SARIDAŞ A. Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19. Eurasian Journal of Critical Care. 2022. doi:10.55994/ejcc.1112050
BibTeX
@article{SARIDA2022,
author = {SARIDAŞ, Ali},
title = {Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19},
journal = {Eurasian Journal of Critical Care},
year = {2022},
doi = {10.55994/ejcc.1112050}
}
EUVIMED